Dttk的个人主页 - 老虎社区

Dttk

Dttk

暂无个人介绍

IP属地：未知

16关注

20粉丝

0主题

0勋章

2021-12-25

like pls

What are MKM Partners 'Black Swan' Internet predictions for 2022?

2021-12-23

like pls

Wall St mints strong gains on rosy economic data, encouraging Omicron update

2021-12-22

like pls

Eisai-Biogen Alzheimer's drug difficult to assess-Japan ministry

2021-12-21

like pls

5 Stocks To Watch For December 21, 2021

2021-12-20

is it the end of the bull run? the start of the bears?

2021-12-20

like pls

Coherus Shares Up 7.2% After FDA Approves Yusimry, Humira Biosimilar

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3572939968720880","uuid":"3572939968720880","gmtCreate":1609847108780,"gmtModify":1617633303477,"name":"Dttk","pinyin":"dttk","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/82269b01d70f98d5770f4418d3911ef9","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":20,"headSize":16,"tweetSize":6,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":15,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.02.14","exceedPercentage":"60.25%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":698618366,"gmtCreate":1640368440374,"gmtModify":1640368440666,"author":{"id":"3572939968720880","authorId":"3572939968720880","name":"Dttk","avatar":"https://static.tigerbbs.com/82269b01d70f98d5770f4418d3911ef9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572939968720880","authorIdStr":"3572939968720880"},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698618366","repostId":"1156159690","repostType":4,"repost":{"id":"1156159690","kind":"news","pubTimestamp":1640335867,"share":"https://www.laohu8.com/m/news/1156159690?lang=&edition=full","pubTime":"2021-12-24 16:51","market":"us","language":"en","title":"What are MKM Partners 'Black Swan' Internet predictions for 2022?","url":"https://stock-news.laohu8.com/highlight/detail?id=1156159690","media":"seekingalpha","summary":"As the year comes to a close, Wall Street analysts are practically falling over themselves with almost daily serious predictions aboutwhat to expect from the tech sector in 2022.So, it should come as no surprise that, like many analysts, MKM Partners managing director Rohit Kulkarni came out with a list of 10 things that could shape the Internet industry next year. However, instead of diving into matters such as revenue growth rates and price-to-earnings ratios, Kulkarni released a slate of \"Bla","content":"<p>As the year comes to a close, Wall Street analysts are practically falling over themselves with almost daily serious predictions aboutwhat to expect from the tech sector in 2022.</p>\n<p>So, it should come as no surprise that, like many analysts, MKM Partners managing director Rohit Kulkarni came out with a list of 10 things that could shape the Internet industry next year. However, instead of diving into matters such as revenue growth rates and price-to-earnings ratios, Kulkarni released a slate of \"Black Swan\"--or, High-Impact-Low-Probability [HILP]--predictions for 2022. Kulkarni said these ideas \"have a very low likelihood of occurrence, but we wouldn't assign a zero probability\" chance of then happening.</p>\n<p>The \"HILP\" predictions Kulkarni has for 2022 include \"consumers [will] return to brick and mortar stores and millennials and Gen Z start watching TV.\" Kulkarni said this could result from Covid-19 vaccinations reaching mass-population levels and reaching an end to the pandemic.</p>\n<p>Kulkarni said Facebook's(NASDAQ:FB)<a href=\"https://laohu8.com/S/CASH\">Meta</a> could launch its own cryptocurrency that could start displacing several traditional fiat currencies, and that mega cap tech companies will manage to not pay any fines to U.S. or European regulators regarding legal cases currently in the works.</p>\n<p>\"We have stopped counting the number of lawsuits facing Big Tech,\" Kulkarni said. \"However, there is fairly limited consensus in the ideas or bills presented to date, and Congress has been focused on the pandemic and infrastructure bill for 2021.</p>\n<ul>\n <li>Kulkarni's other Black Swan predictions are:</li>\n <li>SPAC IPOs will outperform traditional IPOs and direct stock listings.</li>\n <li><a href=\"https://laohu8.com/S/UBER\">Uber</a>(NYSE:UBER)launches its own robotaxi service in several U.S. cities.</li>\n <li><a href=\"https://laohu8.com/S/TWTR\">Twitter</a>(NYSE:TWTR)and Pinterest(NYSE:PINS)are acquired and are no longer independent public companies.</li>\n <li>DoorDash(NYSE:DASH)acquires Instacart for between $40B-50B and spurs a new round of grocery delivery wars.</li>\n <li><a href=\"https://laohu8.com/S/AAPL\">Apple</a>(NASDAQ:AAPL)reaches $10B in annual revenue run rate from advertising due to changes in its iOS ad policies.</li>\n <li>Google's(NASDAQ:GOOG)YouTube get in position to go public.</li>\n <li>Snap(NYSE:SNAP)and TikTok (BDNCE) look to capitalize on their younger audiences by acquiring movie or gaming studios so they can boost their original video content offerings.</li>\n <li>As a \"bonus\" prediction, Kulkarni forecasts that as the pandemic ends, more people will go back to working out at gyms and neighborhood parks, and this will result in difficulty in forecasting sales for the likes of Peloton(NASDAQ:PTON). The home-exercise technology company also had its sails trimmed on Thursday when analysts at Citi cut their price target on Peloton's (PTON) stock to $38 a share on expectations of higher expenses and&nbsp;falling demand for Peloton (PTON) products next year.</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What are MKM Partners 'Black Swan' Internet predictions for 2022?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat are MKM Partners 'Black Swan' Internet predictions for 2022?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-24 16:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3783065-mkm-black-swan-look-at-internet-stocks><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As the year comes to a close, Wall Street analysts are practically falling over themselves with almost daily serious predictions aboutwhat to expect from the tech sector in 2022.\nSo, it should come as...</p>\n\n<a href=\"https://seekingalpha.com/news/3783065-mkm-black-swan-look-at-internet-stocks\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNAP":"Snap Inc","TWTR":"Twitter","PINS":"Pinterest, Inc.","PTON":"Peloton Interactive, Inc.","AAPL":"苹果","GOOG":"谷歌","DASH":"DoorDash, Inc."},"source_url":"https://seekingalpha.com/news/3783065-mkm-black-swan-look-at-internet-stocks","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1156159690","content_text":"As the year comes to a close, Wall Street analysts are practically falling over themselves with almost daily serious predictions aboutwhat to expect from the tech sector in 2022.\nSo, it should come as no surprise that, like many analysts, MKM Partners managing director Rohit Kulkarni came out with a list of 10 things that could shape the Internet industry next year. However, instead of diving into matters such as revenue growth rates and price-to-earnings ratios, Kulkarni released a slate of \"Black Swan\"--or, High-Impact-Low-Probability [HILP]--predictions for 2022. Kulkarni said these ideas \"have a very low likelihood of occurrence, but we wouldn't assign a zero probability\" chance of then happening.\nThe \"HILP\" predictions Kulkarni has for 2022 include \"consumers [will] return to brick and mortar stores and millennials and Gen Z start watching TV.\" Kulkarni said this could result from Covid-19 vaccinations reaching mass-population levels and reaching an end to the pandemic.\nKulkarni said Facebook's(NASDAQ:FB)Meta could launch its own cryptocurrency that could start displacing several traditional fiat currencies, and that mega cap tech companies will manage to not pay any fines to U.S. or European regulators regarding legal cases currently in the works.\n\"We have stopped counting the number of lawsuits facing Big Tech,\" Kulkarni said. \"However, there is fairly limited consensus in the ideas or bills presented to date, and Congress has been focused on the pandemic and infrastructure bill for 2021.\n\nKulkarni's other Black Swan predictions are:\nSPAC IPOs will outperform traditional IPOs and direct stock listings.\nUber(NYSE:UBER)launches its own robotaxi service in several U.S. cities.\nTwitter(NYSE:TWTR)and Pinterest(NYSE:PINS)are acquired and are no longer independent public companies.\nDoorDash(NYSE:DASH)acquires Instacart for between $40B-50B and spurs a new round of grocery delivery wars.\nApple(NASDAQ:AAPL)reaches $10B in annual revenue run rate from advertising due to changes in its iOS ad policies.\nGoogle's(NASDAQ:GOOG)YouTube get in position to go public.\nSnap(NYSE:SNAP)and TikTok (BDNCE) look to capitalize on their younger audiences by acquiring movie or gaming studios so they can boost their original video content offerings.\nAs a \"bonus\" prediction, Kulkarni forecasts that as the pandemic ends, more people will go back to working out at gyms and neighborhood parks, and this will result in difficulty in forecasting sales for the likes of Peloton(NASDAQ:PTON). The home-exercise technology company also had its sails trimmed on Thursday when analysts at Citi cut their price target on Peloton's (PTON) stock to $38 a share on expectations of higher expenses and falling demand for Peloton (PTON) products next year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1083,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691736217,"gmtCreate":1640240866356,"gmtModify":1640240866650,"author":{"id":"3572939968720880","authorId":"3572939968720880","name":"Dttk","avatar":"https://static.tigerbbs.com/82269b01d70f98d5770f4418d3911ef9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572939968720880","authorIdStr":"3572939968720880"},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691736217","repostId":"2193113147","repostType":4,"repost":{"id":"2193113147","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640213688,"share":"https://www.laohu8.com/m/news/2193113147?lang=&edition=full","pubTime":"2021-12-23 06:54","market":"us","language":"en","title":"Wall St mints strong gains on rosy economic data, encouraging Omicron update","url":"https://stock-news.laohu8.com/highlight/detail?id=2193113147","media":"Reuters","summary":"* Tesla jumps as CEO Musk says he has sold 'enough' stock. * Pfizer rises as oral COVID-19 pill wins approval. Dec 22  - Wall Street's main indexes powered higher on Wednesday in a broad rally after upbeat economic data and hopeful developments about the severity of the Omicron coronavirus variant that is sweeping the world.The S&P 500 gained at least 1% for a second straight session, putting it near record levels, as volatility has ratcheted up in the last month of 2021 following the arrival of","content":"<p>* Consumer confidence index increases in December</p>\n<p>* U.S. Q3 economic growth revised slightly higher</p>\n<p>* Tesla jumps as CEO Musk says he has sold 'enough' stock</p>\n<p>* Pfizer rises as oral COVID-19 pill wins approval</p>\n<p>* Indexes up: Dow 0.74%, S&amp;P 1.02%, Nasdaq 1.18% </p>\n<p>Dec 22 (Reuters) - Wall Street's main indexes powered higher on Wednesday in a broad rally after upbeat economic data and hopeful developments about the severity of the Omicron coronavirus variant that is sweeping the world.</p>\n<p>The S&amp;P 500 gained at least 1% for a second straight session, putting it near record levels, as volatility has ratcheted up in the last month of 2021 following the arrival of Omicron and an otherwise strong year for equities.</p>\n<p>A South African study suggested reduced risks of hospitalization and severe disease in people infected with the Omicron variant versus the Delta one, but World Health Organization officials cautioned that it was too soon to draw firm conclusions.</p>\n<p>“We are still struggling for direction in the face of the Omicron outbreak, but in the past few days ... more and more evidence is building that the strain is potentially less severe than prior strains, specifically Delta, which bodes well for economic momentum in 2022,” said Mike Stritch, chief investment officer at BMO Wealth Management.</p>\n<p>The Dow Jones Industrial Average rose 261.19 points, or 0.74%, to 35,753.89, the S&amp;P 500 gained 47.33 points, or 1.02%, to 4,696.56 and the Nasdaq Composite added 180.81 points, or 1.18%, to 15,521.89.</p>\n<p>All major S&amp;P 500 sectors gained, with the consumer discretionary group up 1.7% and technology up 1.3%.</p>\n<p>Tesla Inc shares rose 7.5%, boosting the S&amp;P 500 and Nasdaq. Tesla Chief Executive Elon Musk said in an interview he has sold \"enough stock\" following several weeks of share sales by the billionaire.</p>\n<p>U.S. consumer confidence improved further in December, suggesting the economy would continue to expand in 2022. The survey from the Conference Board showed more consumers planned to buy a house and big-ticket items such as motor vehicles and major household appliances as well as go on vacation over the next six months.</p>\n<p>Other reports showed U.S. home sales increased for a third straight month in November, and that gross domestic product increased at a 2.3% annualized rate in the July-September quarter, revised up from the 2.1% rate estimated last month.</p>\n<p>In another encouraging development against the pandemic, the United States authorized Pfizer Inc's oral antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first at-home treatment for the coronavirus. Pfizer shares rose 1%.</p>\n<p>The benchmark S&amp;P 500 is now up 25% so far in 2021. Still, the environment for equities could be changing heading into next year as the Federal Reserve is expected to begin raising interest rates in 2022 to rein in inflation.</p>\n<p>The market is \"certainly at an extended level of valuation,\" said Rick Meckler, partner at Cherry Lane Investments in New Vernon, New Jersey. “Next year is a more difficult picture, but if inflation is going to be part of the problem, I think investors will certainly choose stocks over bonds.”</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 3.17-to-1 ratio; on Nasdaq, a 1.65-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 15 new 52-week highs and no new lows; the Nasdaq Composite recorded 35 new highs and 99 new lows.</p>\n<p>About 8.6 billion shares changed hands in U.S. exchanges, below the 11.8 billion daily average over the last 20 sessions.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall St mints strong gains on rosy economic data, encouraging Omicron update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall St mints strong gains on rosy economic data, encouraging Omicron update\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-23 06:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>* Consumer confidence index increases in December</p>\n<p>* U.S. Q3 economic growth revised slightly higher</p>\n<p>* Tesla jumps as CEO Musk says he has sold 'enough' stock</p>\n<p>* Pfizer rises as oral COVID-19 pill wins approval</p>\n<p>* Indexes up: Dow 0.74%, S&amp;P 1.02%, Nasdaq 1.18% </p>\n<p>Dec 22 (Reuters) - Wall Street's main indexes powered higher on Wednesday in a broad rally after upbeat economic data and hopeful developments about the severity of the Omicron coronavirus variant that is sweeping the world.</p>\n<p>The S&amp;P 500 gained at least 1% for a second straight session, putting it near record levels, as volatility has ratcheted up in the last month of 2021 following the arrival of Omicron and an otherwise strong year for equities.</p>\n<p>A South African study suggested reduced risks of hospitalization and severe disease in people infected with the Omicron variant versus the Delta one, but World Health Organization officials cautioned that it was too soon to draw firm conclusions.</p>\n<p>“We are still struggling for direction in the face of the Omicron outbreak, but in the past few days ... more and more evidence is building that the strain is potentially less severe than prior strains, specifically Delta, which bodes well for economic momentum in 2022,” said Mike Stritch, chief investment officer at BMO Wealth Management.</p>\n<p>The Dow Jones Industrial Average rose 261.19 points, or 0.74%, to 35,753.89, the S&amp;P 500 gained 47.33 points, or 1.02%, to 4,696.56 and the Nasdaq Composite added 180.81 points, or 1.18%, to 15,521.89.</p>\n<p>All major S&amp;P 500 sectors gained, with the consumer discretionary group up 1.7% and technology up 1.3%.</p>\n<p>Tesla Inc shares rose 7.5%, boosting the S&amp;P 500 and Nasdaq. Tesla Chief Executive Elon Musk said in an interview he has sold \"enough stock\" following several weeks of share sales by the billionaire.</p>\n<p>U.S. consumer confidence improved further in December, suggesting the economy would continue to expand in 2022. The survey from the Conference Board showed more consumers planned to buy a house and big-ticket items such as motor vehicles and major household appliances as well as go on vacation over the next six months.</p>\n<p>Other reports showed U.S. home sales increased for a third straight month in November, and that gross domestic product increased at a 2.3% annualized rate in the July-September quarter, revised up from the 2.1% rate estimated last month.</p>\n<p>In another encouraging development against the pandemic, the United States authorized Pfizer Inc's oral antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first at-home treatment for the coronavirus. Pfizer shares rose 1%.</p>\n<p>The benchmark S&amp;P 500 is now up 25% so far in 2021. Still, the environment for equities could be changing heading into next year as the Federal Reserve is expected to begin raising interest rates in 2022 to rein in inflation.</p>\n<p>The market is \"certainly at an extended level of valuation,\" said Rick Meckler, partner at Cherry Lane Investments in New Vernon, New Jersey. “Next year is a more difficult picture, but if inflation is going to be part of the problem, I think investors will certainly choose stocks over bonds.”</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 3.17-to-1 ratio; on Nasdaq, a 1.65-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 15 new 52-week highs and no new lows; the Nasdaq Composite recorded 35 new highs and 99 new lows.</p>\n<p>About 8.6 billion shares changed hands in U.S. exchanges, below the 11.8 billion daily average over the last 20 sessions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4007":"制药",".IXIC":"NASDAQ Composite","COMP":"Compass, Inc.","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","TSLA":"特斯拉",".DJI":"道琼斯","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193113147","content_text":"* Consumer confidence index increases in December\n* U.S. Q3 economic growth revised slightly higher\n* Tesla jumps as CEO Musk says he has sold 'enough' stock\n* Pfizer rises as oral COVID-19 pill wins approval\n* Indexes up: Dow 0.74%, S&P 1.02%, Nasdaq 1.18% \nDec 22 (Reuters) - Wall Street's main indexes powered higher on Wednesday in a broad rally after upbeat economic data and hopeful developments about the severity of the Omicron coronavirus variant that is sweeping the world.\nThe S&P 500 gained at least 1% for a second straight session, putting it near record levels, as volatility has ratcheted up in the last month of 2021 following the arrival of Omicron and an otherwise strong year for equities.\nA South African study suggested reduced risks of hospitalization and severe disease in people infected with the Omicron variant versus the Delta one, but World Health Organization officials cautioned that it was too soon to draw firm conclusions.\n“We are still struggling for direction in the face of the Omicron outbreak, but in the past few days ... more and more evidence is building that the strain is potentially less severe than prior strains, specifically Delta, which bodes well for economic momentum in 2022,” said Mike Stritch, chief investment officer at BMO Wealth Management.\nThe Dow Jones Industrial Average rose 261.19 points, or 0.74%, to 35,753.89, the S&P 500 gained 47.33 points, or 1.02%, to 4,696.56 and the Nasdaq Composite added 180.81 points, or 1.18%, to 15,521.89.\nAll major S&P 500 sectors gained, with the consumer discretionary group up 1.7% and technology up 1.3%.\nTesla Inc shares rose 7.5%, boosting the S&P 500 and Nasdaq. Tesla Chief Executive Elon Musk said in an interview he has sold \"enough stock\" following several weeks of share sales by the billionaire.\nU.S. consumer confidence improved further in December, suggesting the economy would continue to expand in 2022. The survey from the Conference Board showed more consumers planned to buy a house and big-ticket items such as motor vehicles and major household appliances as well as go on vacation over the next six months.\nOther reports showed U.S. home sales increased for a third straight month in November, and that gross domestic product increased at a 2.3% annualized rate in the July-September quarter, revised up from the 2.1% rate estimated last month.\nIn another encouraging development against the pandemic, the United States authorized Pfizer Inc's oral antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first at-home treatment for the coronavirus. Pfizer shares rose 1%.\nThe benchmark S&P 500 is now up 25% so far in 2021. Still, the environment for equities could be changing heading into next year as the Federal Reserve is expected to begin raising interest rates in 2022 to rein in inflation.\nThe market is \"certainly at an extended level of valuation,\" said Rick Meckler, partner at Cherry Lane Investments in New Vernon, New Jersey. “Next year is a more difficult picture, but if inflation is going to be part of the problem, I think investors will certainly choose stocks over bonds.”\nAdvancing issues outnumbered declining ones on the NYSE by a 3.17-to-1 ratio; on Nasdaq, a 1.65-to-1 ratio favored advancers.\nThe S&P 500 posted 15 new 52-week highs and no new lows; the Nasdaq Composite recorded 35 new highs and 99 new lows.\nAbout 8.6 billion shares changed hands in U.S. exchanges, below the 11.8 billion daily average over the last 20 sessions.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1143,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691851410,"gmtCreate":1640171572378,"gmtModify":1640172023749,"author":{"id":"3572939968720880","authorId":"3572939968720880","name":"Dttk","avatar":"https://static.tigerbbs.com/82269b01d70f98d5770f4418d3911ef9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572939968720880","authorIdStr":"3572939968720880"},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691851410","repostId":"1147037546","repostType":4,"repost":{"id":"1147037546","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640170941,"share":"https://www.laohu8.com/m/news/1147037546?lang=&edition=full","pubTime":"2021-12-22 19:02","market":"us","language":"en","title":"Eisai-Biogen Alzheimer's drug difficult to assess-Japan ministry","url":"https://stock-news.laohu8.com/highlight/detail?id=1147037546","media":"Reuters","summary":"TOKYO (Reuters) -- A Japanese health ministry panel said on Wednesday that inconsistent trial result","content":"<p>TOKYO (Reuters) -- A Japanese health ministry panel said on Wednesday that inconsistent trial results made it difficult to determine the efficacy of an Alzheimer's treatment developed by Eisai Co and Biogen Inc.</p>\n<p>Tokyo-based Eisai and its United States partner filed for Japanese regulatory approval just over a year ago for the drug Aduhelm, which was approved in the United States in June.</p>\n<p>In a statement the panel cited inconsistent results from global Phase III trials and a lack of clinical significance in the drug's ability to reduce plaques in the brain. The panel said it would take another look if further data is submitted.</p>\n<p>Eisai and Biogen have jointly developed three experimental drugs for the brain-wasting disease, which affects millions around the world and has not seen a new treatment in decades.</p>\n<p>Expectations among patient groups and investors for the drug have been on a roller coaster for years. It was nearly abandoned after disappointing trial results in 2019, but Biogen revived it after reviewing data showing that higher doses of the drug could slow disease progression.</p>\n<p>The U.S. Food and Drug Administration (FDA) approved the drug earlier this year despite objections from an outside advisory panel its clinical benefit was unproven.</p>\n<p>Biogen said on Monday it would cut the U.S. price of Aduhelm, known scientifically as aducanumab, in half amid complaints about its high cost and slower than expected sales.</p>\n<p>More than 8 million people in Japan are believed to have dementia or cognitive impairment, while treatment of Alzheimer's patients costs an estimated 7.4 trillion yen ($65 billion) per year.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eisai-Biogen Alzheimer's drug difficult to assess-Japan ministry</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEisai-Biogen Alzheimer's drug difficult to assess-Japan ministry\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-22 19:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TOKYO (Reuters) -- A Japanese health ministry panel said on Wednesday that inconsistent trial results made it difficult to determine the efficacy of an Alzheimer's treatment developed by Eisai Co and Biogen Inc.</p>\n<p>Tokyo-based Eisai and its United States partner filed for Japanese regulatory approval just over a year ago for the drug Aduhelm, which was approved in the United States in June.</p>\n<p>In a statement the panel cited inconsistent results from global Phase III trials and a lack of clinical significance in the drug's ability to reduce plaques in the brain. The panel said it would take another look if further data is submitted.</p>\n<p>Eisai and Biogen have jointly developed three experimental drugs for the brain-wasting disease, which affects millions around the world and has not seen a new treatment in decades.</p>\n<p>Expectations among patient groups and investors for the drug have been on a roller coaster for years. It was nearly abandoned after disappointing trial results in 2019, but Biogen revived it after reviewing data showing that higher doses of the drug could slow disease progression.</p>\n<p>The U.S. Food and Drug Administration (FDA) approved the drug earlier this year despite objections from an outside advisory panel its clinical benefit was unproven.</p>\n<p>Biogen said on Monday it would cut the U.S. price of Aduhelm, known scientifically as aducanumab, in half amid complaints about its high cost and slower than expected sales.</p>\n<p>More than 8 million people in Japan are believed to have dementia or cognitive impairment, while treatment of Alzheimer's patients costs an estimated 7.4 trillion yen ($65 billion) per year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147037546","content_text":"TOKYO (Reuters) -- A Japanese health ministry panel said on Wednesday that inconsistent trial results made it difficult to determine the efficacy of an Alzheimer's treatment developed by Eisai Co and Biogen Inc.\nTokyo-based Eisai and its United States partner filed for Japanese regulatory approval just over a year ago for the drug Aduhelm, which was approved in the United States in June.\nIn a statement the panel cited inconsistent results from global Phase III trials and a lack of clinical significance in the drug's ability to reduce plaques in the brain. The panel said it would take another look if further data is submitted.\nEisai and Biogen have jointly developed three experimental drugs for the brain-wasting disease, which affects millions around the world and has not seen a new treatment in decades.\nExpectations among patient groups and investors for the drug have been on a roller coaster for years. It was nearly abandoned after disappointing trial results in 2019, but Biogen revived it after reviewing data showing that higher doses of the drug could slow disease progression.\nThe U.S. Food and Drug Administration (FDA) approved the drug earlier this year despite objections from an outside advisory panel its clinical benefit was unproven.\nBiogen said on Monday it would cut the U.S. price of Aduhelm, known scientifically as aducanumab, in half amid complaints about its high cost and slower than expected sales.\nMore than 8 million people in Japan are believed to have dementia or cognitive impairment, while treatment of Alzheimer's patients costs an estimated 7.4 trillion yen ($65 billion) per year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1025,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693767959,"gmtCreate":1640083536177,"gmtModify":1640083536416,"author":{"id":"3572939968720880","authorId":"3572939968720880","name":"Dttk","avatar":"https://static.tigerbbs.com/82269b01d70f98d5770f4418d3911ef9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572939968720880","authorIdStr":"3572939968720880"},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/693767959","repostId":"1142422285","repostType":4,"repost":{"id":"1142422285","kind":"news","pubTimestamp":1640083121,"share":"https://www.laohu8.com/m/news/1142422285?lang=&edition=full","pubTime":"2021-12-21 18:38","market":"us","language":"en","title":"5 Stocks To Watch For December 21, 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=1142422285","media":"Benzinga","summary":"Some of the stocks that may grab investor focus today are:\n\nWall Street expects General Mills, Inc. ","content":"<p>Some of the stocks that may grab investor focus today are:</p>\n<ul>\n <li>Wall Street expects&nbsp;<b>General Mills, Inc.</b>&nbsp;to report quarterly earnings at $1.05 per share on revenue of $4.84 billion before the opening bell. General Mills shares slipped 1.3% to $66.91 in after-hours trading.</li>\n <li><b>NIKE, Inc.</b>&nbsp;reported stronger-than-expected results for its second quarter on Monday. Nike shares gained 3.8% to $162.98 in the after-hours trading session.</li>\n <li>Analysts are expecting&nbsp;<b>FactSet Research Systems Inc.</b>&nbsp;to have earned $2.99 per share on revenue of $419.13 million for the latest quarter. The company will release earnings before the markets open. FactSet Research shares gained 1% to $475.44 in after-hours trading.</li>\n <li><b>Micron Technology</b>&nbsp;reported upbeat results for its first quarter and issued strong revenue guidance for the current quarter. Micron shares climbed 6.8% to $87.60 in the after-hours trading session.</li>\n <li>Analysts expect&nbsp;<b>BlackBerry Limited</b>&nbsp;to report a quarterly loss at $0.07 per share on revenue of $177.25 million after the closing bell. BlackBerry shares gained 0.9% to $8.96 in after-hours trading.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Stocks To Watch For December 21, 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Stocks To Watch For December 21, 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 18:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/earnings/21/12/24714267/5-stocks-to-watch-for-december-21-2021><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Some of the stocks that may grab investor focus today are:\n\nWall Street expects General Mills, Inc. to report quarterly earnings at $1.05 per share on revenue of $4.84 billion before the opening bell....</p>\n\n<a href=\"https://www.benzinga.com/news/earnings/21/12/24714267/5-stocks-to-watch-for-december-21-2021\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NKE":"耐克","GIS":"通用磨坊","FDS":"辉盛研究系统","BB":"黑莓","MU":"美光科技"},"source_url":"https://www.benzinga.com/news/earnings/21/12/24714267/5-stocks-to-watch-for-december-21-2021","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142422285","content_text":"Some of the stocks that may grab investor focus today are:\n\nWall Street expects General Mills, Inc. to report quarterly earnings at $1.05 per share on revenue of $4.84 billion before the opening bell. General Mills shares slipped 1.3% to $66.91 in after-hours trading.\nNIKE, Inc. reported stronger-than-expected results for its second quarter on Monday. Nike shares gained 3.8% to $162.98 in the after-hours trading session.\nAnalysts are expecting FactSet Research Systems Inc. to have earned $2.99 per share on revenue of $419.13 million for the latest quarter. The company will release earnings before the markets open. FactSet Research shares gained 1% to $475.44 in after-hours trading.\nMicron Technology reported upbeat results for its first quarter and issued strong revenue guidance for the current quarter. Micron shares climbed 6.8% to $87.60 in the after-hours trading session.\nAnalysts expect BlackBerry Limited to report a quarterly loss at $0.07 per share on revenue of $177.25 million after the closing bell. BlackBerry shares gained 0.9% to $8.96 in after-hours trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":989,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693661156,"gmtCreate":1640014101090,"gmtModify":1640014101375,"author":{"id":"3572939968720880","authorId":"3572939968720880","name":"Dttk","avatar":"https://static.tigerbbs.com/82269b01d70f98d5770f4418d3911ef9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572939968720880","authorIdStr":"3572939968720880"},"themes":[],"htmlText":"is it the end of the bull run? the start of the bears?","listText":"is it the end of the bull run? the start of the bears?","text":"is it the end of the bull run? the start of the bears?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693661156","isVote":1,"tweetType":1,"viewCount":1036,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693608147,"gmtCreate":1640010056700,"gmtModify":1640010056973,"author":{"id":"3572939968720880","authorId":"3572939968720880","name":"Dttk","avatar":"https://static.tigerbbs.com/82269b01d70f98d5770f4418d3911ef9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572939968720880","authorIdStr":"3572939968720880"},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/693608147","repostId":"1189443139","repostType":4,"repost":{"id":"1189443139","kind":"news","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1640008567,"share":"https://www.laohu8.com/m/news/1189443139?lang=&edition=full","pubTime":"2021-12-20 21:56","market":"us","language":"en","title":"Coherus Shares Up 7.2% After FDA Approves Yusimry, Humira Biosimilar","url":"https://stock-news.laohu8.com/highlight/detail?id=1189443139","media":"Dow Jones","summary":"Coherus BioSciences Inc. shares rose 7.2%, to $17.66, premarket Monday after it said the U.S. Food a","content":"<p>Coherus BioSciences Inc. shares rose 7.2%, to $17.66, premarket Monday after it said the U.S. Food and Drug Administration approved Yusimry, a Humira biosimilar product.</p>\n<p>Yusimry is indicated for plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis.</p>\n<p>Approval was based on a data package that demonstrated the biosimilarity of Yusimry to the reference product, Humira.</p>\n<p>Coherus said it plans to launch Yusimry in the U.S. on or after July 1, 2023, per the terms of an agreement with Humira manufacturer AbbVie Inc.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coherus Shares Up 7.2% After FDA Approves Yusimry, Humira Biosimilar</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoherus Shares Up 7.2% After FDA Approves Yusimry, Humira Biosimilar\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-12-20 21:56</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Coherus BioSciences Inc. shares rose 7.2%, to $17.66, premarket Monday after it said the U.S. Food and Drug Administration approved Yusimry, a Humira biosimilar product.</p>\n<p>Yusimry is indicated for plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis.</p>\n<p>Approval was based on a data package that demonstrated the biosimilarity of Yusimry to the reference product, Humira.</p>\n<p>Coherus said it plans to launch Yusimry in the U.S. on or after July 1, 2023, per the terms of an agreement with Humira manufacturer AbbVie Inc.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CHRS":"Coherus Biosciences"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1189443139","content_text":"Coherus BioSciences Inc. shares rose 7.2%, to $17.66, premarket Monday after it said the U.S. Food and Drug Administration approved Yusimry, a Humira biosimilar product.\nYusimry is indicated for plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis.\nApproval was based on a data package that demonstrated the biosimilarity of Yusimry to the reference product, Humira.\nCoherus said it plans to launch Yusimry in the U.S. on or after July 1, 2023, per the terms of an agreement with Humira manufacturer AbbVie Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1165,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":691736217,"gmtCreate":1640240866356,"gmtModify":1640240866650,"author":{"id":"3572939968720880","authorId":"3572939968720880","name":"Dttk","avatar":"https://static.tigerbbs.com/82269b01d70f98d5770f4418d3911ef9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572939968720880","authorIdStr":"3572939968720880"},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691736217","repostId":"2193113147","repostType":4,"repost":{"id":"2193113147","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640213688,"share":"https://www.laohu8.com/m/news/2193113147?lang=&edition=full","pubTime":"2021-12-23 06:54","market":"us","language":"en","title":"Wall St mints strong gains on rosy economic data, encouraging Omicron update","url":"https://stock-news.laohu8.com/highlight/detail?id=2193113147","media":"Reuters","summary":"* Tesla jumps as CEO Musk says he has sold 'enough' stock. * Pfizer rises as oral COVID-19 pill wins approval. Dec 22  - Wall Street's main indexes powered higher on Wednesday in a broad rally after upbeat economic data and hopeful developments about the severity of the Omicron coronavirus variant that is sweeping the world.The S&P 500 gained at least 1% for a second straight session, putting it near record levels, as volatility has ratcheted up in the last month of 2021 following the arrival of","content":"<p>* Consumer confidence index increases in December</p>\n<p>* U.S. Q3 economic growth revised slightly higher</p>\n<p>* Tesla jumps as CEO Musk says he has sold 'enough' stock</p>\n<p>* Pfizer rises as oral COVID-19 pill wins approval</p>\n<p>* Indexes up: Dow 0.74%, S&amp;P 1.02%, Nasdaq 1.18% </p>\n<p>Dec 22 (Reuters) - Wall Street's main indexes powered higher on Wednesday in a broad rally after upbeat economic data and hopeful developments about the severity of the Omicron coronavirus variant that is sweeping the world.</p>\n<p>The S&amp;P 500 gained at least 1% for a second straight session, putting it near record levels, as volatility has ratcheted up in the last month of 2021 following the arrival of Omicron and an otherwise strong year for equities.</p>\n<p>A South African study suggested reduced risks of hospitalization and severe disease in people infected with the Omicron variant versus the Delta one, but World Health Organization officials cautioned that it was too soon to draw firm conclusions.</p>\n<p>“We are still struggling for direction in the face of the Omicron outbreak, but in the past few days ... more and more evidence is building that the strain is potentially less severe than prior strains, specifically Delta, which bodes well for economic momentum in 2022,” said Mike Stritch, chief investment officer at BMO Wealth Management.</p>\n<p>The Dow Jones Industrial Average rose 261.19 points, or 0.74%, to 35,753.89, the S&amp;P 500 gained 47.33 points, or 1.02%, to 4,696.56 and the Nasdaq Composite added 180.81 points, or 1.18%, to 15,521.89.</p>\n<p>All major S&amp;P 500 sectors gained, with the consumer discretionary group up 1.7% and technology up 1.3%.</p>\n<p>Tesla Inc shares rose 7.5%, boosting the S&amp;P 500 and Nasdaq. Tesla Chief Executive Elon Musk said in an interview he has sold \"enough stock\" following several weeks of share sales by the billionaire.</p>\n<p>U.S. consumer confidence improved further in December, suggesting the economy would continue to expand in 2022. The survey from the Conference Board showed more consumers planned to buy a house and big-ticket items such as motor vehicles and major household appliances as well as go on vacation over the next six months.</p>\n<p>Other reports showed U.S. home sales increased for a third straight month in November, and that gross domestic product increased at a 2.3% annualized rate in the July-September quarter, revised up from the 2.1% rate estimated last month.</p>\n<p>In another encouraging development against the pandemic, the United States authorized Pfizer Inc's oral antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first at-home treatment for the coronavirus. Pfizer shares rose 1%.</p>\n<p>The benchmark S&amp;P 500 is now up 25% so far in 2021. Still, the environment for equities could be changing heading into next year as the Federal Reserve is expected to begin raising interest rates in 2022 to rein in inflation.</p>\n<p>The market is \"certainly at an extended level of valuation,\" said Rick Meckler, partner at Cherry Lane Investments in New Vernon, New Jersey. “Next year is a more difficult picture, but if inflation is going to be part of the problem, I think investors will certainly choose stocks over bonds.”</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 3.17-to-1 ratio; on Nasdaq, a 1.65-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 15 new 52-week highs and no new lows; the Nasdaq Composite recorded 35 new highs and 99 new lows.</p>\n<p>About 8.6 billion shares changed hands in U.S. exchanges, below the 11.8 billion daily average over the last 20 sessions.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall St mints strong gains on rosy economic data, encouraging Omicron update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall St mints strong gains on rosy economic data, encouraging Omicron update\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-23 06:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>* Consumer confidence index increases in December</p>\n<p>* U.S. Q3 economic growth revised slightly higher</p>\n<p>* Tesla jumps as CEO Musk says he has sold 'enough' stock</p>\n<p>* Pfizer rises as oral COVID-19 pill wins approval</p>\n<p>* Indexes up: Dow 0.74%, S&amp;P 1.02%, Nasdaq 1.18% </p>\n<p>Dec 22 (Reuters) - Wall Street's main indexes powered higher on Wednesday in a broad rally after upbeat economic data and hopeful developments about the severity of the Omicron coronavirus variant that is sweeping the world.</p>\n<p>The S&amp;P 500 gained at least 1% for a second straight session, putting it near record levels, as volatility has ratcheted up in the last month of 2021 following the arrival of Omicron and an otherwise strong year for equities.</p>\n<p>A South African study suggested reduced risks of hospitalization and severe disease in people infected with the Omicron variant versus the Delta one, but World Health Organization officials cautioned that it was too soon to draw firm conclusions.</p>\n<p>“We are still struggling for direction in the face of the Omicron outbreak, but in the past few days ... more and more evidence is building that the strain is potentially less severe than prior strains, specifically Delta, which bodes well for economic momentum in 2022,” said Mike Stritch, chief investment officer at BMO Wealth Management.</p>\n<p>The Dow Jones Industrial Average rose 261.19 points, or 0.74%, to 35,753.89, the S&amp;P 500 gained 47.33 points, or 1.02%, to 4,696.56 and the Nasdaq Composite added 180.81 points, or 1.18%, to 15,521.89.</p>\n<p>All major S&amp;P 500 sectors gained, with the consumer discretionary group up 1.7% and technology up 1.3%.</p>\n<p>Tesla Inc shares rose 7.5%, boosting the S&amp;P 500 and Nasdaq. Tesla Chief Executive Elon Musk said in an interview he has sold \"enough stock\" following several weeks of share sales by the billionaire.</p>\n<p>U.S. consumer confidence improved further in December, suggesting the economy would continue to expand in 2022. The survey from the Conference Board showed more consumers planned to buy a house and big-ticket items such as motor vehicles and major household appliances as well as go on vacation over the next six months.</p>\n<p>Other reports showed U.S. home sales increased for a third straight month in November, and that gross domestic product increased at a 2.3% annualized rate in the July-September quarter, revised up from the 2.1% rate estimated last month.</p>\n<p>In another encouraging development against the pandemic, the United States authorized Pfizer Inc's oral antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first at-home treatment for the coronavirus. Pfizer shares rose 1%.</p>\n<p>The benchmark S&amp;P 500 is now up 25% so far in 2021. Still, the environment for equities could be changing heading into next year as the Federal Reserve is expected to begin raising interest rates in 2022 to rein in inflation.</p>\n<p>The market is \"certainly at an extended level of valuation,\" said Rick Meckler, partner at Cherry Lane Investments in New Vernon, New Jersey. “Next year is a more difficult picture, but if inflation is going to be part of the problem, I think investors will certainly choose stocks over bonds.”</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 3.17-to-1 ratio; on Nasdaq, a 1.65-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 15 new 52-week highs and no new lows; the Nasdaq Composite recorded 35 new highs and 99 new lows.</p>\n<p>About 8.6 billion shares changed hands in U.S. exchanges, below the 11.8 billion daily average over the last 20 sessions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4007":"制药",".IXIC":"NASDAQ Composite","COMP":"Compass, Inc.","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","TSLA":"特斯拉",".DJI":"道琼斯","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193113147","content_text":"* Consumer confidence index increases in December\n* U.S. Q3 economic growth revised slightly higher\n* Tesla jumps as CEO Musk says he has sold 'enough' stock\n* Pfizer rises as oral COVID-19 pill wins approval\n* Indexes up: Dow 0.74%, S&P 1.02%, Nasdaq 1.18% \nDec 22 (Reuters) - Wall Street's main indexes powered higher on Wednesday in a broad rally after upbeat economic data and hopeful developments about the severity of the Omicron coronavirus variant that is sweeping the world.\nThe S&P 500 gained at least 1% for a second straight session, putting it near record levels, as volatility has ratcheted up in the last month of 2021 following the arrival of Omicron and an otherwise strong year for equities.\nA South African study suggested reduced risks of hospitalization and severe disease in people infected with the Omicron variant versus the Delta one, but World Health Organization officials cautioned that it was too soon to draw firm conclusions.\n“We are still struggling for direction in the face of the Omicron outbreak, but in the past few days ... more and more evidence is building that the strain is potentially less severe than prior strains, specifically Delta, which bodes well for economic momentum in 2022,” said Mike Stritch, chief investment officer at BMO Wealth Management.\nThe Dow Jones Industrial Average rose 261.19 points, or 0.74%, to 35,753.89, the S&P 500 gained 47.33 points, or 1.02%, to 4,696.56 and the Nasdaq Composite added 180.81 points, or 1.18%, to 15,521.89.\nAll major S&P 500 sectors gained, with the consumer discretionary group up 1.7% and technology up 1.3%.\nTesla Inc shares rose 7.5%, boosting the S&P 500 and Nasdaq. Tesla Chief Executive Elon Musk said in an interview he has sold \"enough stock\" following several weeks of share sales by the billionaire.\nU.S. consumer confidence improved further in December, suggesting the economy would continue to expand in 2022. The survey from the Conference Board showed more consumers planned to buy a house and big-ticket items such as motor vehicles and major household appliances as well as go on vacation over the next six months.\nOther reports showed U.S. home sales increased for a third straight month in November, and that gross domestic product increased at a 2.3% annualized rate in the July-September quarter, revised up from the 2.1% rate estimated last month.\nIn another encouraging development against the pandemic, the United States authorized Pfizer Inc's oral antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first at-home treatment for the coronavirus. Pfizer shares rose 1%.\nThe benchmark S&P 500 is now up 25% so far in 2021. Still, the environment for equities could be changing heading into next year as the Federal Reserve is expected to begin raising interest rates in 2022 to rein in inflation.\nThe market is \"certainly at an extended level of valuation,\" said Rick Meckler, partner at Cherry Lane Investments in New Vernon, New Jersey. “Next year is a more difficult picture, but if inflation is going to be part of the problem, I think investors will certainly choose stocks over bonds.”\nAdvancing issues outnumbered declining ones on the NYSE by a 3.17-to-1 ratio; on Nasdaq, a 1.65-to-1 ratio favored advancers.\nThe S&P 500 posted 15 new 52-week highs and no new lows; the Nasdaq Composite recorded 35 new highs and 99 new lows.\nAbout 8.6 billion shares changed hands in U.S. exchanges, below the 11.8 billion daily average over the last 20 sessions.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1143,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693767959,"gmtCreate":1640083536177,"gmtModify":1640083536416,"author":{"id":"3572939968720880","authorId":"3572939968720880","name":"Dttk","avatar":"https://static.tigerbbs.com/82269b01d70f98d5770f4418d3911ef9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572939968720880","authorIdStr":"3572939968720880"},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/693767959","repostId":"1142422285","repostType":4,"repost":{"id":"1142422285","kind":"news","pubTimestamp":1640083121,"share":"https://www.laohu8.com/m/news/1142422285?lang=&edition=full","pubTime":"2021-12-21 18:38","market":"us","language":"en","title":"5 Stocks To Watch For December 21, 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=1142422285","media":"Benzinga","summary":"Some of the stocks that may grab investor focus today are:\n\nWall Street expects General Mills, Inc. ","content":"<p>Some of the stocks that may grab investor focus today are:</p>\n<ul>\n <li>Wall Street expects&nbsp;<b>General Mills, Inc.</b>&nbsp;to report quarterly earnings at $1.05 per share on revenue of $4.84 billion before the opening bell. General Mills shares slipped 1.3% to $66.91 in after-hours trading.</li>\n <li><b>NIKE, Inc.</b>&nbsp;reported stronger-than-expected results for its second quarter on Monday. Nike shares gained 3.8% to $162.98 in the after-hours trading session.</li>\n <li>Analysts are expecting&nbsp;<b>FactSet Research Systems Inc.</b>&nbsp;to have earned $2.99 per share on revenue of $419.13 million for the latest quarter. The company will release earnings before the markets open. FactSet Research shares gained 1% to $475.44 in after-hours trading.</li>\n <li><b>Micron Technology</b>&nbsp;reported upbeat results for its first quarter and issued strong revenue guidance for the current quarter. Micron shares climbed 6.8% to $87.60 in the after-hours trading session.</li>\n <li>Analysts expect&nbsp;<b>BlackBerry Limited</b>&nbsp;to report a quarterly loss at $0.07 per share on revenue of $177.25 million after the closing bell. BlackBerry shares gained 0.9% to $8.96 in after-hours trading.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Stocks To Watch For December 21, 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Stocks To Watch For December 21, 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 18:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/earnings/21/12/24714267/5-stocks-to-watch-for-december-21-2021><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Some of the stocks that may grab investor focus today are:\n\nWall Street expects General Mills, Inc. to report quarterly earnings at $1.05 per share on revenue of $4.84 billion before the opening bell....</p>\n\n<a href=\"https://www.benzinga.com/news/earnings/21/12/24714267/5-stocks-to-watch-for-december-21-2021\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NKE":"耐克","GIS":"通用磨坊","FDS":"辉盛研究系统","BB":"黑莓","MU":"美光科技"},"source_url":"https://www.benzinga.com/news/earnings/21/12/24714267/5-stocks-to-watch-for-december-21-2021","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142422285","content_text":"Some of the stocks that may grab investor focus today are:\n\nWall Street expects General Mills, Inc. to report quarterly earnings at $1.05 per share on revenue of $4.84 billion before the opening bell. General Mills shares slipped 1.3% to $66.91 in after-hours trading.\nNIKE, Inc. reported stronger-than-expected results for its second quarter on Monday. Nike shares gained 3.8% to $162.98 in the after-hours trading session.\nAnalysts are expecting FactSet Research Systems Inc. to have earned $2.99 per share on revenue of $419.13 million for the latest quarter. The company will release earnings before the markets open. FactSet Research shares gained 1% to $475.44 in after-hours trading.\nMicron Technology reported upbeat results for its first quarter and issued strong revenue guidance for the current quarter. Micron shares climbed 6.8% to $87.60 in the after-hours trading session.\nAnalysts expect BlackBerry Limited to report a quarterly loss at $0.07 per share on revenue of $177.25 million after the closing bell. BlackBerry shares gained 0.9% to $8.96 in after-hours trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":989,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693608147,"gmtCreate":1640010056700,"gmtModify":1640010056973,"author":{"id":"3572939968720880","authorId":"3572939968720880","name":"Dttk","avatar":"https://static.tigerbbs.com/82269b01d70f98d5770f4418d3911ef9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572939968720880","authorIdStr":"3572939968720880"},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/693608147","repostId":"1189443139","repostType":4,"repost":{"id":"1189443139","kind":"news","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1640008567,"share":"https://www.laohu8.com/m/news/1189443139?lang=&edition=full","pubTime":"2021-12-20 21:56","market":"us","language":"en","title":"Coherus Shares Up 7.2% After FDA Approves Yusimry, Humira Biosimilar","url":"https://stock-news.laohu8.com/highlight/detail?id=1189443139","media":"Dow Jones","summary":"Coherus BioSciences Inc. shares rose 7.2%, to $17.66, premarket Monday after it said the U.S. Food a","content":"<p>Coherus BioSciences Inc. shares rose 7.2%, to $17.66, premarket Monday after it said the U.S. Food and Drug Administration approved Yusimry, a Humira biosimilar product.</p>\n<p>Yusimry is indicated for plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis.</p>\n<p>Approval was based on a data package that demonstrated the biosimilarity of Yusimry to the reference product, Humira.</p>\n<p>Coherus said it plans to launch Yusimry in the U.S. on or after July 1, 2023, per the terms of an agreement with Humira manufacturer AbbVie Inc.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coherus Shares Up 7.2% After FDA Approves Yusimry, Humira Biosimilar</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoherus Shares Up 7.2% After FDA Approves Yusimry, Humira Biosimilar\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-12-20 21:56</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Coherus BioSciences Inc. shares rose 7.2%, to $17.66, premarket Monday after it said the U.S. Food and Drug Administration approved Yusimry, a Humira biosimilar product.</p>\n<p>Yusimry is indicated for plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis.</p>\n<p>Approval was based on a data package that demonstrated the biosimilarity of Yusimry to the reference product, Humira.</p>\n<p>Coherus said it plans to launch Yusimry in the U.S. on or after July 1, 2023, per the terms of an agreement with Humira manufacturer AbbVie Inc.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CHRS":"Coherus Biosciences"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1189443139","content_text":"Coherus BioSciences Inc. shares rose 7.2%, to $17.66, premarket Monday after it said the U.S. Food and Drug Administration approved Yusimry, a Humira biosimilar product.\nYusimry is indicated for plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis.\nApproval was based on a data package that demonstrated the biosimilarity of Yusimry to the reference product, Humira.\nCoherus said it plans to launch Yusimry in the U.S. on or after July 1, 2023, per the terms of an agreement with Humira manufacturer AbbVie Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1165,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691851410,"gmtCreate":1640171572378,"gmtModify":1640172023749,"author":{"id":"3572939968720880","authorId":"3572939968720880","name":"Dttk","avatar":"https://static.tigerbbs.com/82269b01d70f98d5770f4418d3911ef9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572939968720880","authorIdStr":"3572939968720880"},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691851410","repostId":"1147037546","repostType":4,"isVote":1,"tweetType":1,"viewCount":1025,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698618366,"gmtCreate":1640368440374,"gmtModify":1640368440666,"author":{"id":"3572939968720880","authorId":"3572939968720880","name":"Dttk","avatar":"https://static.tigerbbs.com/82269b01d70f98d5770f4418d3911ef9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572939968720880","authorIdStr":"3572939968720880"},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698618366","repostId":"1156159690","repostType":4,"repost":{"id":"1156159690","kind":"news","pubTimestamp":1640335867,"share":"https://www.laohu8.com/m/news/1156159690?lang=&edition=full","pubTime":"2021-12-24 16:51","market":"us","language":"en","title":"What are MKM Partners 'Black Swan' Internet predictions for 2022?","url":"https://stock-news.laohu8.com/highlight/detail?id=1156159690","media":"seekingalpha","summary":"As the year comes to a close, Wall Street analysts are practically falling over themselves with almost daily serious predictions aboutwhat to expect from the tech sector in 2022.So, it should come as no surprise that, like many analysts, MKM Partners managing director Rohit Kulkarni came out with a list of 10 things that could shape the Internet industry next year. However, instead of diving into matters such as revenue growth rates and price-to-earnings ratios, Kulkarni released a slate of \"Bla","content":"<p>As the year comes to a close, Wall Street analysts are practically falling over themselves with almost daily serious predictions aboutwhat to expect from the tech sector in 2022.</p>\n<p>So, it should come as no surprise that, like many analysts, MKM Partners managing director Rohit Kulkarni came out with a list of 10 things that could shape the Internet industry next year. However, instead of diving into matters such as revenue growth rates and price-to-earnings ratios, Kulkarni released a slate of \"Black Swan\"--or, High-Impact-Low-Probability [HILP]--predictions for 2022. Kulkarni said these ideas \"have a very low likelihood of occurrence, but we wouldn't assign a zero probability\" chance of then happening.</p>\n<p>The \"HILP\" predictions Kulkarni has for 2022 include \"consumers [will] return to brick and mortar stores and millennials and Gen Z start watching TV.\" Kulkarni said this could result from Covid-19 vaccinations reaching mass-population levels and reaching an end to the pandemic.</p>\n<p>Kulkarni said Facebook's(NASDAQ:FB)<a href=\"https://laohu8.com/S/CASH\">Meta</a> could launch its own cryptocurrency that could start displacing several traditional fiat currencies, and that mega cap tech companies will manage to not pay any fines to U.S. or European regulators regarding legal cases currently in the works.</p>\n<p>\"We have stopped counting the number of lawsuits facing Big Tech,\" Kulkarni said. \"However, there is fairly limited consensus in the ideas or bills presented to date, and Congress has been focused on the pandemic and infrastructure bill for 2021.</p>\n<ul>\n <li>Kulkarni's other Black Swan predictions are:</li>\n <li>SPAC IPOs will outperform traditional IPOs and direct stock listings.</li>\n <li><a href=\"https://laohu8.com/S/UBER\">Uber</a>(NYSE:UBER)launches its own robotaxi service in several U.S. cities.</li>\n <li><a href=\"https://laohu8.com/S/TWTR\">Twitter</a>(NYSE:TWTR)and Pinterest(NYSE:PINS)are acquired and are no longer independent public companies.</li>\n <li>DoorDash(NYSE:DASH)acquires Instacart for between $40B-50B and spurs a new round of grocery delivery wars.</li>\n <li><a href=\"https://laohu8.com/S/AAPL\">Apple</a>(NASDAQ:AAPL)reaches $10B in annual revenue run rate from advertising due to changes in its iOS ad policies.</li>\n <li>Google's(NASDAQ:GOOG)YouTube get in position to go public.</li>\n <li>Snap(NYSE:SNAP)and TikTok (BDNCE) look to capitalize on their younger audiences by acquiring movie or gaming studios so they can boost their original video content offerings.</li>\n <li>As a \"bonus\" prediction, Kulkarni forecasts that as the pandemic ends, more people will go back to working out at gyms and neighborhood parks, and this will result in difficulty in forecasting sales for the likes of Peloton(NASDAQ:PTON). The home-exercise technology company also had its sails trimmed on Thursday when analysts at Citi cut their price target on Peloton's (PTON) stock to $38 a share on expectations of higher expenses and&nbsp;falling demand for Peloton (PTON) products next year.</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What are MKM Partners 'Black Swan' Internet predictions for 2022?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat are MKM Partners 'Black Swan' Internet predictions for 2022?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-24 16:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3783065-mkm-black-swan-look-at-internet-stocks><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As the year comes to a close, Wall Street analysts are practically falling over themselves with almost daily serious predictions aboutwhat to expect from the tech sector in 2022.\nSo, it should come as...</p>\n\n<a href=\"https://seekingalpha.com/news/3783065-mkm-black-swan-look-at-internet-stocks\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNAP":"Snap Inc","TWTR":"Twitter","PINS":"Pinterest, Inc.","PTON":"Peloton Interactive, Inc.","AAPL":"苹果","GOOG":"谷歌","DASH":"DoorDash, Inc."},"source_url":"https://seekingalpha.com/news/3783065-mkm-black-swan-look-at-internet-stocks","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1156159690","content_text":"As the year comes to a close, Wall Street analysts are practically falling over themselves with almost daily serious predictions aboutwhat to expect from the tech sector in 2022.\nSo, it should come as no surprise that, like many analysts, MKM Partners managing director Rohit Kulkarni came out with a list of 10 things that could shape the Internet industry next year. However, instead of diving into matters such as revenue growth rates and price-to-earnings ratios, Kulkarni released a slate of \"Black Swan\"--or, High-Impact-Low-Probability [HILP]--predictions for 2022. Kulkarni said these ideas \"have a very low likelihood of occurrence, but we wouldn't assign a zero probability\" chance of then happening.\nThe \"HILP\" predictions Kulkarni has for 2022 include \"consumers [will] return to brick and mortar stores and millennials and Gen Z start watching TV.\" Kulkarni said this could result from Covid-19 vaccinations reaching mass-population levels and reaching an end to the pandemic.\nKulkarni said Facebook's(NASDAQ:FB)Meta could launch its own cryptocurrency that could start displacing several traditional fiat currencies, and that mega cap tech companies will manage to not pay any fines to U.S. or European regulators regarding legal cases currently in the works.\n\"We have stopped counting the number of lawsuits facing Big Tech,\" Kulkarni said. \"However, there is fairly limited consensus in the ideas or bills presented to date, and Congress has been focused on the pandemic and infrastructure bill for 2021.\n\nKulkarni's other Black Swan predictions are:\nSPAC IPOs will outperform traditional IPOs and direct stock listings.\nUber(NYSE:UBER)launches its own robotaxi service in several U.S. cities.\nTwitter(NYSE:TWTR)and Pinterest(NYSE:PINS)are acquired and are no longer independent public companies.\nDoorDash(NYSE:DASH)acquires Instacart for between $40B-50B and spurs a new round of grocery delivery wars.\nApple(NASDAQ:AAPL)reaches $10B in annual revenue run rate from advertising due to changes in its iOS ad policies.\nGoogle's(NASDAQ:GOOG)YouTube get in position to go public.\nSnap(NYSE:SNAP)and TikTok (BDNCE) look to capitalize on their younger audiences by acquiring movie or gaming studios so they can boost their original video content offerings.\nAs a \"bonus\" prediction, Kulkarni forecasts that as the pandemic ends, more people will go back to working out at gyms and neighborhood parks, and this will result in difficulty in forecasting sales for the likes of Peloton(NASDAQ:PTON). The home-exercise technology company also had its sails trimmed on Thursday when analysts at Citi cut their price target on Peloton's (PTON) stock to $38 a share on expectations of higher expenses and falling demand for Peloton (PTON) products next year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1083,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693661156,"gmtCreate":1640014101090,"gmtModify":1640014101375,"author":{"id":"3572939968720880","authorId":"3572939968720880","name":"Dttk","avatar":"https://static.tigerbbs.com/82269b01d70f98d5770f4418d3911ef9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572939968720880","authorIdStr":"3572939968720880"},"themes":[],"htmlText":"is it the end of the bull run? the start of the bears?","listText":"is it the end of the bull run? the start of the bears?","text":"is it the end of the bull run? the start of the bears?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693661156","isVote":1,"tweetType":1,"viewCount":1036,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}